Directorate Change

IP2IPO Group PLC
08 October 2004


For Immediate Release                                    8 October 2004



                                IP2IPO Group plc



           Bruce Campbell to join IP2IPO as Chief Scientific Officer



IP2IPO Group plc ('IP2IPO') (AIM: IPO), the intellectual property company that
commercialises university technology, announces that Dr. Bruce Campbell has
joined the board of IP2IPO as Chief Scientific Officer.



Dr. Campbell joins IP2IPO from Neurocrine Biosciences, Inc ('Neurocrine') the
NASDAQ listed biotechnology company which last year licensed its 'Indiplon'
compound for the treatment of insomnia to Pfizer, the terms of which included
$100m in up-front fees and $300m in milestone payments. Dr. Campbell  was Senior
VP of Development at Neurocine and since 1998 he had overall responsibility for
directing Neurocrine's selection and advancement of drug candidates from
research into clinical development. This has culminated in advancing eight novel
drugs into clinical trials for the treatment of insomnia, depression, anxiety,
brain cancer, multiple sclerosis, type I diabetes, and endometriosis.



Dr. Campbell joined Neurocrine after 27 years at Servier (United Kingdom), where
he served as Research & Development Director. In this capacity, he was
responsible the development and registration of more than seven drugs and
vaccines in the United Kingdom and English speaking countries throughout the
world.



Dr. Campbell has been a Director and European Chairman of the Drug Information
Association, a member of the European ICH Safety Working Party and secretary of
the Society for Pharmaceutical Medicine.  He is also a visiting Professor in
Pharmacology at King's College London setting up and teaching BSc and MSc
courses on Drug Design and Development over the last 13 years. He has specific
expertise on the practical and regulatory aspects of clinical pharmacology,
pharmacokinetics, metabolism and toxicology in new drug development and has
written standard texts on these subjects and published more than 100 scientific
papers.



Commenting on today's announcement, David Norwood, Chief Executive Officer of
IP2IPO said: 'This appointment is a great coup for IP2IPO.  Bruce's fantastic
track record demonstrates how well he understands drug development and he is
immensely well respected within the biotechnology and pharmaceutical industries.
I am absolutely delighted to be able to welcome Bruce to the Company.'



For more information please contact:


IP2IPO
David Norwood, Chief Executive Officer                      020 7242 9900

Buchanan Communications
Mark Court,  Tim Anderson                                   020 7466 5000



Notes to editors



IP2IPO



IP2IPO is an intellectual property (IP) company that specialises in
commercialising university technology. The Company was founded in 2001 and
listed on AIM in October 2003.



IP2IPO's first partnership was with the University of Oxford. In return for an
investment of £20 million, IP2IPO has acquired 50 per cent of the University of
Oxford's equity in spin-out companies and technology licenses based on
intellectual property created at the Chemistry Department until 2015. In
November 2003, IP2IPO created a £5 million seed capital fund for investing in
spin-out companies across the University of Oxford, not just those originating
within the Chemistry Department.



In March 2002, IP2IPO entered into a second long-term partnership with the
University of Southampton.  Under the terms of this partnership, IP2IPO is
committed to working with the University of Southampton in the identification
and facilitation of spin-out companies from across the University of Southampton
and to investing £5 million in early-stage University of Southampton spin-out
companies over a four year period in return for equity stakes in those
companies.  In addition, IP2IPO also received a 20 per cent stake in Southampton
Asset Management Limited, a company that has been formed to hold the
University's equity stakes in its future spin-out companies. The partnership has
a term of at least 25 years.



IP2IPO entered into its third long-term partnership in May 2003 with King's
College London.  IP2IPO will work with King's College London to help identify
and progress commercialisation opportunities as well as invest £5 million in
seed capital in spin-out companies from King's College London over a five year
period in return for equity stakes in those companies.  In addition, IP2IPO will
receive 20 per cent of King's College London's equity in spin-out companies and
technology licenses.  The partnership has an initial term of 25 years.



In October 2003, IP2IPO announced a fourth partnership with the Centre for Novel
Agricultural Products ('CNAP'), based at the University of York. CNAP is a
flagship research centre that specialises in plant and microbial gene discovery.
Under the terms of the partnership a new company, Amaethon Limited, has been
created which has the right to commercialise CNAP's IP for 25 years. IP2IPO has
committed to invest £1.15m in Amaethon Limited in return for a one third equity
stake in Amaethon Limited (the remaining equity being owned by the University of
York) and will also invest in the spin-out companies based on CNAP's IP which
Amaethon Limited creates.



In July 2004, IP2IPO acquired a strategic 20% stake in Techtran Group Limited ('
Techtran'). Techtran has a long-term technology commercialisation contract with
the University of Leeds. Under the terms of the contract Techtran receives a
significant (30%) interest in spin-out companies created and technology licences
negotiated in return for the provision of technology transfer services to the
University.



In June 2004, IP2IPO acquired Top Technology Ventures Limited, an investment
adviser to early stage technology funds. This combines IP2IPO's expertise in the
creation of new ventures based on world leading university IP with Top
Technology focus on making early stage venture capital investments.




                      This information is provided by RNS
            The company news service from the London Stock Exchange